ALTITUDE Autopsy Shows What Went Wrong With Aliskiren
In its short lifespan the direct renin inhibitor aliskiren (a.k.a., Rasilez or Tekturna) rapidly declined from being a highly promising, first-of-its kind drug to a major failure. The death blow was struck last December with the early termination of the ALTITUDE trial, after the data and safety monitoring committee found an increased risk in patients taking aliskiren. Now the final results of the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints have been presented at Kidney Week 2012 in San Diego and simultaneously published in the New England Journal of Medicine. 8,561 type 2 diabetics at high risk f...
Source: CardiologyNetwork.com - October 13, 2013 Category: Cardiology Authors: Indian Diabetics Foundation Team Source Type: forums